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Bisphosphonates (BPs) are well known clinically used drugs, commonly applied to 
treat osteoclast-mediated bone resorption. Some clinically used BPs were demonstrat-
ed to be able to inhibit the activity of matrix metalloproteinases (MMPs) (1), a protease 
family required to fully degrade all the components of the extracellular matrix during 
connective tissue remodelling (2). Combining the arylsulfonamide function with the 
bisphosphonic group, several compounds were synthesized to obtain selective inhibi-
tors of MMPs. The aim of the present work is to compare the effects on cell adhesion, 
cytotoxicity, inflammatory response occurrence and matrix turnover process in an in 
vitro model of primary human gingival fibroblasts (HGFs) treated with newly synthe-
sized sulfonamide BPs and with zoledronic acid (ZA), a clinically used drug. West-
ern blot was used to measure Procollagen I, β1 integrin MMP-8 and MMP-9, phase 
contrast and MTT for cell viability, LDH was performed for toxicity evaluation, ELISA 
for Prostaglandin E2 (PGE2) secretion assessment. When compared with ZA, the treat-
ment with the newly synthetized compounds shows increasing viability, Procollagen I 
expression and decreased expression of β1 integrin in HGFs. Higher levels of released 
LDH, PGE2 and MMP-9 expression are recorded in ZA-treated HGFs. Increased levels 
of MMP-8 are recorded in newly synthetized compounds-treated samples.These find-
ings imply that new BPs could accelerate the physiological matrix turnover, they are 
more able to preserve the soft tissue surrounding bone as they have neither inflam-
matory effects nor toxicity, along with reduced effects on the cell viability, which are 
instead typical side effects of ZA administration. We can conclude that the newly 
synthesized compounds are better tolerated, leading to the hypothesis that their use 
leads to connective tissues side effects reduction compared to clinically used drugs, 
even though several studies are required to deeply investigate the signaling cascades 
involved in the mechanism of action of these new BPs. 
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